| book details |

Improving and Accelerating Therapeutic Development for Nervous System Disorders: Workshop Summary

By (author) Forum on Neuroscience and Nervous System Disorders, By (author) Board on Health Sciences Policy, By (author) Institute of Medicine, Edited by Sheena M. Posey Norris, Edited by Diana E. Pankevich, Edited by Miriam Davis, Edited by Bruce M. Altevogt

This book is currently unavailable. Enquire to check if we can source a used copy

| enquire |

| book description |

Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop participants discussed challenges in neuroscience research for enabling faster entry of potential treatments into first-in-human trials, explored how new and emerging tools and technologies may improve the efficiency of research, and considered mechanisms to facilitate a more effective and efficient development pipeline. There are several challenges to the current drug development pipeline for nervous system disorders. The fundamental etiology and pathophysiology of many nervous system disorders are unknown and the brain is inaccessible to study, making it difficult to develop accurate models. Patient heterogeneity is high, disease pathology can occur years to decades before becoming clinically apparent, and diagnostic and treatment biomarkers are lacking. In addition, the lack of validated targets, limitations related to the predictive validity of animal models - the extent to which the model predicts clinical efficacy - and regulatory barriers can also impede translation and drug development for nervous system disorders. Improving and Accelerating Therapeutic Development for Nervous System Disorders identifies avenues for moving directly from cellular models to human trials, minimizing the need for animal models to test efficacy, and discusses the potential benefits and risks of such an approach. This report is a timely discussion of opportunities to improve early drug development with a focus toward preclinical trials.

| product details |

| other options |

| back |

| your trolley |

To view the items in your trolley please sign in.

| sign in |

| specials |

The Thing at 52

Mr. Ross Montgomery
Hardback
40 pages
was: R 363.95
now: R 345.95
Usually dispatched in 3 to 4 weeks as supplier is out of stock

The Thing at 52 is aÂ beautiful picture book about friendship, loneliness and learning how to say goodbye.

| more |

| add to trolley |

The Silent Patient: The record-breaking, multimillion copy Sunday Times bestselling thriller and TikTok sensation

Alex Michaelides
Paperback / softback
352 pages
was: R 280.95
now: R 252.95
Available from overseas. Dispatched in aprox 4-8 weeks as local supplier is out of stock

With film rights snapped up by an Oscar winning Hollywood production company, rights sold in a world record 43 territories, and rave blurbs from David Baldacci, Lee Child and A.

| more |

| add to trolley |

Free Your Mind: The new world of manipulation and how to resist it

Laura Dodsworth
Paperback / softback
384 pages
was: R 300.95
now: R 270.95
Available from overseas. Dispatched in aprox 4-8 weeks as local supplier is out of stock

The Instant Sunday Times Bestseller Learn how to recognise and resist the daily attempts to control and manipulate your mind.

| more |

| add to trolley |